Dear Infliximab/Etanercept user,
If you have filled out the survey, please accept our thanks as no further involvement is required. If you have not had a chance to take the survey yet, I would appreciate your participation to complete the survey. Only you can tell us your views and opinions toward biologics and biosimilar.
If you have Rheumatoid arthritis and using infliximab (Remicade, Remsima, Inflectra or Flixabi) or etanercept (Enbrel or Benepali) you are eligible to participate in this research. It takes less than 10 minutes to complete the questionnaires.
Your participation is entirely voluntary. The data collected in this study are entirely confidential, and the website used for data collection is secure in order to ensure confidentiality.
To participate go to: surveymonkey.co.uk/r/keeleb...
This survey has been approved by the Ethical Review Panel of Keele University. There are no risks associated with participating in this study. The survey collects no identifying information of any respondent. All responses will be anonymous.
The survey is closed on May 31st, 2017.
If you have any questions regarding the survey or this research project in general, please contact Mohammed Aladul at (email@example.com) or his supervisor Prof. Stephen Chapman at (firstname.lastname@example.org) or Tel: 01782734131. If you have any questions concerning your rights as a research participant, please contact the Nicola Leighton (Keele University Research Governance Officer) at: 01782 733306. Or: email@example.com.
Thank you in advance for your participation.